A generic image of a pen, a calculator and sheets
Markets

Flexion Therapeutics Sees Relative Strength Rating Improve To 75

A generic image of a pen, a calculator and sheets
Shutterstock photo

The Relative Strength ( RS ) Rating for Flexion Therapeutics ( FLXN ) entered a higher percentile Friday, as it got a lift from 69 to 75.

[ibd-display-video id=2102289 width=50 float=left autostart=true] This proprietary rating tracks technical performance by using a 1 (worst) to 99 (best) score that indicates how a stock's price action over the trailing 52 weeks stacks up against all the other stocks in our database.

Over 100 years of market history reveals that the market's biggest winners typically have an 80 or higher RS Rating as they begin their largest climbs. See if Flexion Therapeutics can continue to rebound and clear that threshold.

Looking For The Best Stocks To Buy And Watch? Start Here

Flexion Therapeutics is not currently showing a potential buy point. See if the stock goes on to build a promising consolidation that could kick off a new price move.

The company showed -44% earnings growth in the latest quarterly report. Revenue rose 0%.

Flexion Therapeutics earns the No. 200 rank among its peers in the Medical-Biomed/Biotech industry group. Celgene ( CELG ), Corcept Therapeutics ( CORT ) and Ligand Pharmaceuticals ( LGND ) are among the top 5 highly rated stocks within the group.

RELATED:

Biotech And Pharmaceutical Industry And Stock News

IBD Stock Rating Upgrades: Rising Relative Strength

Why Should You Use IBD's Relative Strength Rating?

How Relative Strength Line Can Help You Judge A Stock

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

CORT RS FLXN CELG LGND

Other Topics

Stocks

Latest Markets Videos